Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.

Abstract

Adenovirus infection is a serious and often fatal complication in hematopoietic stem cell transplant patients. There are currently no FDA-approved therapies for adenovirus infection, with only anecdotal, off-label uses described for a variety of anti-viral agents or immune therapies. We report the first case of successful eradication of disseminated adenovirus infection by the novel antiviral agent CMX001 in a severely immunocompromised pediatric stem cell transplant recipient following failure to respond to intravenous cidofovir. Complete clinical and virologic response was documented; virologic and pharmacokinetic data are reported. CMX001 is a promising new oral antiviral agent under development for the prophylaxis and treatment of severe infections caused by double-stranded DNA viruses including adenovirus in immunocompromised patients.

• Authors: Kris Paolino, Jane Sande, Evelio Perez, Brett Loechelt, Barbara Jantausch, Wendy Painter, Margaret Anderson, Tim Tippin, E Randall Lanier, Terry Fry, Roberta L DeBiasi
• Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (J Clin Virol) Vol. 50 Issue 2 Pg. 167-70 (Feb 2011) ISSN: 1873-5967 [Electronic] Netherlands
• PMID: 21094081 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2010 Elsevier B.V. All rights reserved.

Chemical References

• Antiviral Agents
• Organophosphonates
• brincidofovir
• Cytosine

Topics

• Adenovirus Infections, Human (complications, drug therapy)
• Antiviral Agents (therapeutic use)
• Child
• Cytosine (analogs & derivatives, therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunocompromised Host
• Organophosphonates (therapeutic use)
• Polymerase Chain Reaction